Table 3.
Reference | na | Design | Therapy | Follow-up | Primary end point | Primary result |
---|---|---|---|---|---|---|
Edelman et al.9 | 58 | Longitudinal | CSII simple dosing | 4 months | HbA1c | Significant reduction in HbA1c |
Jennings et al.10 | 20 | RCT | CSII or conventional insulin | 4 months | HbA1c | Significant reduction in HbA1c favoring CSII |
Kapitza et al.11 | 6 | Feasibility | CSII with simple insulin pump | 7 days | Glycemic profiles | Stable or improved glycemic profiles |
Labrousse-Lhermine et al.12 | 59 | Longitudinal | CSII simple dosing, two regimens | 3 years | HbA1c | Significant reduction in HbA1c for 2 CSII regimens |
Lane13 | 9 | Feasibility | CSII with U-500 insulin | 3 months | HbA1c | Significant reduction in HbA1c |
Parkner et al.14 | 21 | Crossover | Basal CSII or insulin glargine | 2 periods of 8 days | Insulin and glycemic profiles | Improved insulin and glycemic profiles favoring CSII |
Testa et al.15 | 126 | RCT | CSII or MDI | 24 weeks | Treatment satisfaction | Improved treatment satisfaction favoring CSII |
Subjects randomized.